Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17297961 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL17297790 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL17888208 | 0.94 | TDP1 (0.52) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL17376555 | 0.87 | TSHR (0.51) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL19195010 | 0.86 | TDP1 (0.45) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL10508730 | 0.86 | RAB9A (0.46) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL19477704 | 0.86 | TDP1 (0.45) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL10508734 | 0.86 | RAB9A (0.46) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL3122498 | 0.86 | TSHR (0.50) | SMN1; SMN2MAPTLIN28ATDP1RAB9A | |
| SCHEMBL19102403 | 0.85 | TDP1 (0.44) | SMN1; SMN2MAPTLIN28ATDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-11-19 | — | — | US | disclosed |
| EP-2935214-B1 | 1,4-PYRIDONE COMPOUNDS | EPIZYME INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-07-26 | — | — | US | disclosed |
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-07-26 | — | — | US | disclosed |
| US-20180134692-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180134692-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180065954-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-03-08 | — | — | US | disclosed |
| US-20180065954-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-03-08 | — | — | US | disclosed |
| EP-2935264-B1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160152604-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-06-02 | — | — | US | disclosed |
| US-20160031907-A1 | Substituted Benzene Compounds | Epizyme, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-20160031907-A1 | Substituted Benzene Compounds | Epizyme, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-20150344427-A1 | 1,4-PYRIDONE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | CYP4B1, PDXK, CYP1B1 | SMN1; SMN2 2930/4885MAPT 4124/4885LIN28A 4694/4885 |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | SMN1; SMN2 4624/4885MAPT 4172/4885LIN28A 4458/4885 |
| US-20180134692-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | CYP4B1, PDXK, CYP1B1 | SMN1; SMN2 2930/4885MAPT 4124/4885LIN28A 4694/4885 |
| US-20160031907-A1 | Substituted Benzene Compounds | CYP1B1, CYP4B1, CYP2B6 | SMN1; SMN2 2439/4885MAPT 4438/4885LIN28A 4167/4885 |
| US-20150344427-A1 | 1,4-PYRIDONE COMPOUNDS | PDXK, PNPO, PLPBP | SMN1; SMN2 2354/4885MAPT 3910/4885LIN28A 4726/4885 |
| US-20160152604-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS | SMN1; SMN2 3597/4885MAPT 4252/4885LIN28A 3920/4885 |
| US-20180065954-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS | SMN1; SMN2 3597/4885MAPT 4252/4885LIN28A 3920/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | SMN1; SMN2 3067/4885MAPT 4681/4885LIN28A 4466/4885 |
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | SMN1; SMN2 3952/4885MAPT 4625/4885LIN28A 3768/4885 |
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | SMN1; SMN2 4624/4885MAPT 4172/4885LIN28A 4458/4885 |
| US-20160194316-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | SMN1; SMN2 2744/4885MAPT 4181/4885LIN28A 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.